Comparison of Two Rapid Whole-Blood Tests for Helicobacter pylori Infection in Chinese Patients

Por Leung, Wai Keung, Chan, Francis K. L., Falk, Matthew S., Suen, Roamy, Sung, Joseph J. Y.
Publicado em 1998

Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design

Por Chen, Ping, Deng, Ya-Li, Bergqvist, Simon, Falk, Matthew D, Liu, Wei, Timofeevski, Sergei, Brooun, Alexei
Publicado no Protein Sci (2014)

Controlling signaling with a specifically designed G(i)-coupled receptor

Por Coward, Peter, Wada, H. Gary, Falk, Matthew S., Chan, Sam D. H., Meng, Fan, Akil, Huda, Conklin, Bruce R.
Publicado em 1998

Enzyme kinetics and distinct modulation of the protein kinase N family of kinases by lipid activators and small molecule inhibitors

Por Falk, Matthew D., Liu, Wei, Bolaños, Ben, Unsal-Kacmaz, Keziban, Klippel, Anke, Grant, Stephan, Brooun, Alexei, Timofeevski, Sergei
Publicado em 2014

Substrate Selection Influences Molecular Recognition in a Screen for Lymphoid Tyrosine Phosphatase Inhibitors

Por Kulkarni, Rhushikesh A., Vellore, Nadeem A., Bliss, Matthew R., Stanford, Stephanie M., Falk, Matthew D., Bottini, Nunzio, Baron, Riccardo, Barrios, Amy M.
Publicado em 2013

High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45

Por Stanford, Stephanie M., Panchal, Rekha G., Walker, Logan M., Wu, Dennis J., Falk, Matthew D., Mitra, Sayantan, Damle, Sagar S., Ruble, David, Kaltcheva, Teodora, Zhang, Sheng, Zhang, Zhong-Yin, Bavari, Sina, Barrios, Amy M., Bottini, Nunzio
Publicado em 2012

Discovery of a Novel Series of Inhibitors of Lymphoid Tyrosine Phosphatase with Activity in Human T Cells

Por Stanford, Stephanie M., Krishnamurthy, Divya, Falk, Matthew D., Messina, Rossella, Debnath, Bikash, Li, Sheng, Liu, Tong, Kazemi, Roza, Dahl, Russell, He, Yantao, Yu, Xiao, Chan, Andrew C., Zhang, Zhong-Yin, Barrios, Amy M., Woods, Virgil L., Neamati, Nouri, Bottini, Nunzio
Publicado em 2011

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

Por Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Publicado em 2013

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Por Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, Fantin, Valeria R.
Publicado no Proc Natl Acad Sci U S A (2015)